Your session is about to expire
← Back to Search
NNC0194-0499 + Semaglutide for Fatty Liver Disease
Study Summary
This trial is testing if a new drug, NNC0194-0499, in combination with semaglutide, can reduce liver damage in patients with non-alcoholic steatohepatitis (NASH).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what quantity are medical facilities in this jurisdiction engaging with the trial?
"Currently, 59 healthcare facilities are enrolling participants in this experiment. These medical clinics span from Hershey to Waco and Seattle with many other locations in between. It is advisable that prospective patients select the closest clinic to avoid unnecessary travel if they decide to join the trial."
What is the highest possible enrollment capacity for this investigation?
"Absolutely. It is clear from the information found on clinicaltrials.gov that this medical trial, which started being advertised on August 31st 2021, is still open for enrollment. 672 individuals must be recruited across 59 sites to complete the study."
Are investigators accepting new participants into this research project?
"According to the details hosted on clinicaltrials.gov, this medical trial is actively searching for participants. The study was first listed on August 31st 2021 and has recently been updated as of November 10th 2022."
What medical benefits does Semaglutide 3 mg/mL provide?
"Semaglutide 3 mg/mL is a popular remedy for chronic weight management. It can also work to alleviate the symptoms of patients with comorbidities related to their bodyweight when combined with exercise and calorie-restriction diets."
What prior experiments have been performed involving Semaglutide 3 mg/mL?
"At present, 58 operational studies are being conducted on Semaglutide 3 mg/mL with 27 of those trials in Phase 3. Predominantly located in Loma Linda, California, there is an abundance of research sites currently running tests for this drug at 3907 different clinics around the world."
Has the Food and Drug Administration granted its stamp of approval to Semaglutide 3 mg/mL?
"There is some evidence to suggest Semaglutide 3mg/mL's safety, indicating a score of 2. Efficacy data has not been collected as this is currently a Phase 2 trial."
How does this investigation compare to previous experiments in its field?
"As of now, 58 clinical studies for Semaglutide 3 mg/mL are operating in 772 cities and 55 countries. The initial trial was sponsored by Novo Nordisk A/S in 2018 with 1387 participants taking part until Phase 4 Drug Approval was completed. Since then, 123 trials have concluded their experiments."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novo Nordisk Investigational Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger